Los Angeles Capital Management LLC Has $1.43 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Los Angeles Capital Management LLC trimmed its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 43.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,240 shares of the biotechnology company’s stock after selling 65,250 shares during the quarter. Los Angeles Capital Management LLC’s holdings in ADMA Biologics were worth $1,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ADMA. Creative Planning lifted its holdings in ADMA Biologics by 52.0% in the 3rd quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock worth $1,098,000 after purchasing an additional 18,800 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in ADMA Biologics in the 3rd quarter worth approximately $2,658,000. New York State Teachers Retirement System acquired a new stake in ADMA Biologics in the 3rd quarter worth approximately $1,821,000. Finally, SteelPeak Wealth LLC acquired a new stake in ADMA Biologics in the 3rd quarter worth approximately $471,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $16.39 on Friday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $16.75 and its two-hundred day moving average is $17.98. The company has a market cap of $3.87 billion, a P/E ratio of 58.54 and a beta of 0.75. ADMA Biologics, Inc. has a 12 month low of $5.08 and a 12 month high of $23.64.

Analyst Ratings Changes

Several research firms recently weighed in on ADMA. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.